Table 1 Patient data and response to... | American Society of Hematology

Table 1

Patient data and response to pharicin B and/or ATRA

No.	Sex	Age, y	FAB subtype	Chromosome	Blasts %	WBC (× 10⁹/L)	CD11b-positive cells %				P
No.	Sex	Age, y	FAB subtype	Chromosome	Blasts %	WBC (× 10⁹/L)	DMSO	pharicin B	ATRA	pharicin B/ATRA	*	†
1	F	25	M4	46, XX	56.5	23.5	11.06 ± 0.50	13.29 ± 0.53	11.28 ± 0.58	15.48 ± 0.21	> .05	> .05
2	M	77	M4	ND	75.5	52.8	18.72 ± 0.37	20.00 ± 1.69	26.76 ± 2.90	29.40 ± 3.15	> .05	> .05
3	M	33	M5	46, XY	86	27.7	1.80 ± 0.85	2.54 ± 0.34	2.32 ± 0.54	2.64 ± 0.17	> .05	> .05
4	M	19	M5	46, XY	80.5	21.8	10.80 ± 0.61	17.21 ± 1.01	14.02 ± 0.34	19.94 ± 1.77	< .02	> .05
5	M	39	M3	46, XY, PML-RARα⁺	80.5	101	5.07 ± 0.37	5.91 ± 0.38	36.98 ± 0.44	85.12 ± 1.51	> .05	< .001
6	M	43	M3	46, XY, PML-RARα⁺	94.5	98	0.46 ± 0.49	0.56 ± 0.27	38.30 ± 0.26	89.00 ± 0.16	> .05	< .001
7	F	36	M4	ND	70.5	46.8	18.60 ± 1.14	24.19 ± 1.21	34.26 ± 3.87	49.17 ± 3.79	< .02	< .001
8	M	27	M4	ND	83.5	17.9	23.77 ± 0.72	29.08 ± 0.72	34.25 ± 1.33	48.06 ± 1.00	< .01	< .001
9	M	53	M4	46, XY	79	69.8	8.53 ± 0.22	13.25 ± 0.65	33.70 ± 2.78	56.60 ± 1.31	< .001	< .001
10	M	61	M5	ND	83.5	2.3	12.65 ± 2.62	26.92 ± 0.89	32.82 ± 2.71	61.92 ± 1.93	< .001	< .001
11	M	20	M5	ND	77.6	161.2	15.02 ± 1.08	40.07 ± 0.87	37.38 ± 0.64	67.02 ± 1.46	< .001	< .001
12	F	53	M5	46, XX	92	58.1	22.47 ± 0.90	28.10 ± 0.98	40.81 ± 1.87	54.86 ± 2.63	< .001	< .002

No.	Sex	Age, y	FAB subtype	Chromosome	Blasts %	WBC (× 10⁹/L)	CD11b-positive cells %				P
No.	Sex	Age, y	FAB subtype	Chromosome	Blasts %	WBC (× 10⁹/L)	DMSO	pharicin B	ATRA	pharicin B/ATRA	*	†
1	F	25	M4	46, XX	56.5	23.5	11.06 ± 0.50	13.29 ± 0.53	11.28 ± 0.58	15.48 ± 0.21	> .05	> .05
2	M	77	M4	ND	75.5	52.8	18.72 ± 0.37	20.00 ± 1.69	26.76 ± 2.90	29.40 ± 3.15	> .05	> .05
3	M	33	M5	46, XY	86	27.7	1.80 ± 0.85	2.54 ± 0.34	2.32 ± 0.54	2.64 ± 0.17	> .05	> .05
4	M	19	M5	46, XY	80.5	21.8	10.80 ± 0.61	17.21 ± 1.01	14.02 ± 0.34	19.94 ± 1.77	< .02	> .05
5	M	39	M3	46, XY, PML-RARα⁺	80.5	101	5.07 ± 0.37	5.91 ± 0.38	36.98 ± 0.44	85.12 ± 1.51	> .05	< .001
6	M	43	M3	46, XY, PML-RARα⁺	94.5	98	0.46 ± 0.49	0.56 ± 0.27	38.30 ± 0.26	89.00 ± 0.16	> .05	< .001
7	F	36	M4	ND	70.5	46.8	18.60 ± 1.14	24.19 ± 1.21	34.26 ± 3.87	49.17 ± 3.79	< .02	< .001
8	M	27	M4	ND	83.5	17.9	23.77 ± 0.72	29.08 ± 0.72	34.25 ± 1.33	48.06 ± 1.00	< .01	< .001
9	M	53	M4	46, XY	79	69.8	8.53 ± 0.22	13.25 ± 0.65	33.70 ± 2.78	56.60 ± 1.31	< .001	< .001
10	M	61	M5	ND	83.5	2.3	12.65 ± 2.62	26.92 ± 0.89	32.82 ± 2.71	61.92 ± 1.93	< .001	< .001
11	M	20	M5	ND	77.6	161.2	15.02 ± 1.08	40.07 ± 0.87	37.38 ± 0.64	67.02 ± 1.46	< .001	< .001
12	F	53	M5	46, XX	92	58.1	22.47 ± 0.90	28.10 ± 0.98	40.81 ± 1.87	54.86 ± 2.63	< .001	< .002

ND indicates not done.

P value between pharicin B and DMSO.

P value between pharicin B/ATRA and pharicin B or ATRA treatment alone